idelalisib (Compound)

Synonyms:Idelalisib, 870281-82-6, CAL-101, Zydelig, GS-1101, CAL 101, CAL101, (S)-2-(1-((9H-Purin-6-yl)amino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one, 1146702-54-6, Idelalisib (CAL-101), CAL-101 (Idelalisib, GS-1101), GS 1101, (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one, 5-Fluoro-3-phenyl-2-((S)-1-(9H-purin-6-ylamino)-propyl)-3H-quinazolin-4-one, YG57I8T5M0, CHEMBL2216870, CHEBI:82701, Idelalisib; CAL-101, 5-fluoro-3-phenyl-2-((1s)-1-(9h-purin-6-ylamino)propyl)-4(3h)-quinazolinone, 5-fluoro-3-phenyl-2-[(1S)-1-(7H-purin-6-ylamino)propyl]quinazolin-4-one, 5-fluoro-3-phenyl-2-[(1S)-1-(3H-purin-6-ylamino)propyl]quinazolin-4(3H)-one, 5-Fluoro-3-Phenyl-2-[(1s)-1-(7h-Purin-6-Ylamino)propyl]quinazolin-4(3h)-One, 1453810-72-4, Idelalisib [INN], Idelalisib [USAN:INN], UNII-YG57I8T5M0, Idealisib, C22H18FN7O, Zydelig (TN), IDELALISIB [MI], IDELALISIB [JAN], IDELALISIB [USAN], IDELALISIB [VANDF], IDELALISIB [WHO-DD], MLS006010985, Idelalisib (JAN/USAN/INN), SCHEMBL356400, GTPL6741, IDELALISIB [ORANGE BOOK], SCHEMBL16782604, HSDB 8408, AMY9239, CAL-101/CAL101, EX-A330, GS-11CAL-101, BCPP000307, DTXSID701007266, BCP02532, EX-A1242, BDBM50403068, MFCD19443647, NSC759224, NSC762828, NSC800771, s2226, AKOS022186334, Idelalisib (CAL-101,GS-1101), BCP9000471, CCG-264949, CS-0256, DB09054, NSC-759224, NSC-762828, NSC-800771, CAL-101 (GS-1101), NCGC00262603-01, NCGC00262603-02, NCGC00262603-04, AC-28394, AC-36641, HY-13026, IC489666, SMR004702787, SW219823-1, A-1138, D10560, EN300-7412931, J-517532, Q5908266, BRD-K60866521-001-01-4, (S)-5-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)-propyl]-3H-quinazolin-4-one, 4(3H)-QUINAZOLINONE, 5-FLUORO-3-PHENYL-2-((1S)-1-(1H-PURIN-6-YLAMINO)PROPYL)-, 4(3H)-QUINAZOLINONE, 5-FLUORO-3-PHENYL-2-((1S)-1-(9H-PURIN-6-YLAMINO)PROPYL)-, 4(3H)-Quinazolinone,5-fluoro-3-phenyl-2-[(1S)-1-(1H-purin-6-ylamino)propyl]-, 5-fluoro-3-phenyl-2-[(1S)-1-[(9H-purin-6-yl)amino]propyl]-3,4-dihydroquinazolin-4-one, 40L

Pubchem:PUBCHEM:11625818

Id:43821c93-abba-575d-9074-efa6f808f376

Description:nan

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View idelalisib's neighborhood in the knowledge graph.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for idelalisib.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with idelalisib.

Results found

Linked to

	Label	Description
	BRD-K60866521-001-07-1 Substance (Entity type)	A Substance
	idelalisib (db4e95c8-dea4-4c79-83bb-78eda552f2e7) Collection (Entity type)	Metadatata for idelalisib
	DCSTRUCT ID 04878 Collection (Entity type)	DrugPage Collection: (DrugCentralID:04878; PubChem_CID:11625818, FILE=drugcentral_drug_04878.json)
	Levomepromazine in similarity relationship with idelalisib Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	Temozolomide in similarity relationship with idelalisib Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	idelalisib positively regulates LRIG1 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	idelalisib positively regulates ALOX5AP Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	idelalisib negatively regulates TOB1 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	idelalisib negatively regulates REG1A Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	idelalisib in similarity relationship with Ifosfamide Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS